
Jan 21 (Reuters) -
CEPI BACKS UPDATED ZAIRE EBOLAVIRUS VACCINE THAT AIMS TO IMPROVE VACCINE AFFORDABILITY AND ACCESSIBILITY FOR LOW- AND MIDDLE-INCOME COUNTRIES
CEPI: BACKED BY UP TO $30 MLN IN CEPI FUNDING, MSD WILL LEVERAGE HILLEMAN LABORATORIES TO DEVELOP EBOLA VACCINE WITH UPDATED MANUFACTURING PROCESS
CEPI: WILL ALSO FUND PHASE 3 IMMUNOBRIDGING CLINICAL TRIAL IN COUNTRIES IN AFRICA WHERE CURRENT EBOLA VACCINE IS APPROVED FOR USE